Myasthenia Gravis

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat anti–acetylcholine receptor– and anti–muscle-specific kinase–positive generalized myasthenia gravis (gMG) in adult patients; administration is subcutaneous and takes approximately 15 minutes.

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.

Myasthenia gravis is becoming increasingly common around the world, with a resulting disease burden beset by high health care resource utilization, decreased quality of life, and worsened mental health.

With 2 new self-administration methods, patients living with generalized myasthenia gravis can be more empowered to manage their treatment with greater independence and control.

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular blockade from rocuronium bromide or vecuronium bromide.

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations and those who did not experience exacerbations.

Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe disease subtype.

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

Review the most impactful news about myasthenia gravis (MG) in 2024.

Finding similar frequencies of positive acetylcholine receptor antibodies in patients with ocular and generalized myasthenia gravis (MG), a Danish research team posits that ocular disease is most likely a more moderate form of generalized MG—not a fully separate condition.

Across treatments, rozanolixizumab and batoclimab were most effective, though rozanolixizumab carried increased risk of adverse events (AEs) and serious AEs.

Myasthenia Gravis Foundation of America (MGFA) class correlates with activities of daily living and other clinical characteristics on a group level, but individual variability is significant between patients of the same MGFA class.

Recent insights shed light onto the most effective diagnostic tools for laryngeal myasthenia gravis (MG), a poorly understood and often misdiagnosed condition, is most reliably.

For some patients with myasthenia gravis (MG), activity and sleep were associated with reported fatigue and symptom levels.

A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).

Patients with myasthenia gravis (MG) largely expressed negative emotions around MG treatment and symptom burden in patient focus groups and on MG social media discussion boards.

The data come from a systematic review of over 90 studies between 1952 through 2022, which found that both prevalence and incidence rates have than doubled throughout the study period.

Researchers introduce a telemedicine system powered by artificial intelligence (AI) that automatically scores neuromuscular examinations, offering the potential to enhance patient monitoring, reduce variability in clinical trials, and improve access to care for neuromuscular disorders like myasthenia gravis.

This new study investigated the impact of COVID-19 on patients with myasthenia gravis, finding that although most patients did not experience severe COVID-19, a significant portion suffered postinfection exacerbations.